IDRSF News and Press, Idorsia Ltd Registered Shares

2026-06-23 12:55:55 ET So, since my October comparison article , " Teva Vs. Viatris: Who Will Dominate In President Trump's America? ," Viatris Inc.'s ( VTRS ) shares have risen 54.1%, outperforming Sandoz Group [45.3% return] ( SDZNY ), its key competitor in the generic...

2026-06-22 13:15:04 ET Deutsche Bank analyst issues HOLD recommendation for IDRSF on June 22, 2026 04:00PM ET. The previous analyst recommendation was Hold. IDRSF was trading at $7.5 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...

The findings demonstrate that aprocitentan may help reduce the risk of kidney disease progression, cardiovascular events, and mortality in patients with resistant hypertension. Allschwil, Switzerland – June 01, 2026 Idorsia Ltd (SIX: IDIA) announces new analyses from the Phase 3 PRE...

2026-03-31 14:32:09 ET Idorsia Ltd (IDRSF) Discusses Positive Phase II Results for Daridorexant in Pediatric Insomnia and Neurodevelopmental Disorders March 31, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: Idorsia Ltd (IDRSF) Discusses ...

2026-02-26 14:17:47 ET Idorsia Ltd (IDRSF) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Company Participants Srishti Gupta - CEO & Executive Director Arno Groenewoud - Executive VP & CFO Conference Call Participants Raghuram Selvaraju - H...

2026-02-26 11:54:02 ET More on Idorsia Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha’s Quant Rating on Idorsia ...

2026-01-14 18:35:59 ET Idorsia Ltd (IDRSF) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age Brigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symp...

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland &#x...

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medi...